Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q1 2025 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2025-05-14 · accession 0000902664-25-002321

$73.0M
Reported value
11
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$45.8M62.7%5,664,548CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$6.4M8.73%161,600CommonSOLE
00534A102IVVDINVIVYD INC$5.6M7.67%9,248,250CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$4.2M5.74%121,200CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$2.6M3.53%385,680CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$2.4M3.34%55,200CommonSOLE
35168W103GUTSFRACTYL HEALTH INC$2.2M3.03%1,856,117CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$1.4M1.86%1,019,498CommonSOLE
231269309CRISCURIS INC$1.1M1.50%521,059CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$858,6761.18%67,400CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$521,9820.72%185,100CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.